Sustained Suprachoroidal Delivery of Therapeutic Peptidesfor Ocular Diseases

摘要： 目前治疗新生血管老年性黄斑变性和黄斑水肿的方法是 每月或每两个月直接注射到玻璃体中。有很大的需求 具有更高疗效的新药物以及其他较少使用的药物 行政管理。我们已经开发出在这些动物模型中具有强大活性的多肽。 疾病以及能够在体内释放多肽的持续递送载体 几个月来一直处于受控状态。在这里，我们建议测试以下假设：我们的 缓释药物可成功注射到脉络膜上腔后 视网膜中的活性多肽将被释放到受影响的组织中以抑制 新生血管和水肿。计算模型将被用来量化药物 并将其扩展到人眼模型。这项提议是多学科的，是 该团队在动物模型、粒子设计和制造方面的专业知识大大加强了这一点， 多肽开发和计算方法。

Summary: Current therapies for neo-vascular age-related macular degeneration and macular edema are injected directly into the vitreous on a monthly or bi-monthly schedule. There is a great need for new agents with improved efficacy as well as other modes of delivery for less frequent administration. We have developed peptides with potent activity in animal models of these diseases as well as sustained delivery vehicles which are able to release the peptides in a controlled manner for multiple months. Here we propose to test the hypothesis that our sustained delivery drug can be injected successfully into the suprachoridal space behind the retina from which the active peptides will be released into the affected tissues to inhibit neovascularization and edema. Computational modeling will be used to quantify the drug delivery and extend it to a model of the human eye. The proposal is multidisciplinary and is greatly strengthened by the team's expertise in animal models, particle design and fabrication, peptide development, and computational methods.